Conference Programme

COPD8 Final Programme 20-22 June 2012

Wednesday 20th June (am)

8.30 - 9.30am

ME1 New treatments for COPD Hall 11a
  Prof Peter Barnes (UK)

ME2 The role of the nurse in optimising patient care Media Suite
  Sam Prigmore (UK) & Sandy Walmsley (UK)

ME3  Novartis: Implementing treatment guidelines - appropriate use of ICS Hall 11b
  Prof Wisia Wedzicha (UK)

9.30 - 10.30am

ME4 Almirall: 24 hours in the life of a COPD patient Hall 11a
  Prof Dennis Shale (UK)

ME5 Patient education what is required Hall 11b
  Monica Fletcher (UK) & Prof Sally Singh (UK)

ME6 Setting up and running a good and full HOS-AR Media Suite
  Jo Riley (UK)

10.30 – 11.00am Refreshment Break Hall 4

11.00am -1.00pm Hall 1

PS1. The 21st century health care challenge of chronic non-communicable diseases
11:00 Welcome Prof Rob Stockley (UK) & Prof Sue Hill (UK)
11:10 Opening Speech Rt Hon Simon Burns (UK)
11:35 Extent of global problem Prof Sonia Buist (USA)
11:50 Challenge for healthcare systems Prof Marc Decramer (Belg)
12:05 Social determinants of non-communicable disease Dr Ruth Bell (UK)
12:20 A technology driven perspective
  on responding to the challenge Kevin Dean (UK)
12:35 How do we interrupt the Tsunami? Round table discussion

1.00 – 2.00pm Lunch Break Hall 4

Wednesday 20th June (pm)

2.00 – 3.30pm

BS1.  Neutrophil Migration Hall 11b
This session reconsiders the potential role of the neutrophil in the pathophysiology of COPD exploring recent knowledge of cell function
Chair: Prof Edwin Chilvers (UK) & Dr Liz Sapey (UK)
2:00 Introduction: The traditional role of the neutrophil Prof Rob Stockley (UK)
2:05 Neutrophil transit Prof Edwin Chilvers (UK)
2:20 Neutrophil migration Prof Gerard Nash (UK)
2:35 Neutrophil NETs Dr Liz Sapey (UK)
2:50 Neutrophil and tissue damage Dr Alison Condliffe (UK)
3:05 Panel discussion

CS1. Vitamins and COPD Hall 11a
This session introduces the increasing evidence to implicate vitamins in the pathophysiology of COPD
Chair: Prof Marc Decramer (Belg)
2:00 Introduction: Why would vitamins be
  considered to be important Prof Marc Decramer (Belg)
2:10 Rationale for use of Vitamin D in Chronic Disease Dr Alice Turner (UK)
2:30 Vitamin D Deficiency in animal models Dr Graeme Zosky (Aus)
2:50 Vitamin D Status in COPD and effects of supplementation Dr Wim Janssens (Belg)
3:10 Panel discussion

CD1. Improving the management of the disease Hall 1
This session will explore different aspects of supporting patients and clinicians to manage the disease better
Chair: Prof Sue Hill (UK) & Prof Mike Morgan (UK)
2:00 Introduction – the patient perspective Dame Helena Shovelton (UK)
  & John Walsh (USA)
2:20 Self management and supported self management Prof Christine Jenkins (Aus)
2:35 Smoking cessation making it happen Dr Alex Bobak (UK)
2:50 Decision support aids – can they help the busy clinician? Prof Mike Pearson (UK)
3:05 Telehealth and monitoring –
  when is it useful and cost effective? Prof Josep Roca (Spain)
3:20 Panel discussion

3.30 – 4.00pm Refreshment Break Hall 4

4.00 -6.00pm Hall 1

PS2. COPD and Co-morbidity
4:00 Co-morbidity, which diseases? Prof Bart Celli (USA)
4:15 The heart and the lung, how they are linked Prof Bill MacNee (UK)
4:30 COPD and Lung Cancer Dr Javier Zulueta (Spain)
4:45 COPD and IPF: common start, different end point Dr George Washko (USA)
5:00 Round table discussion
5:45 Presentation of COPD Hall of Fame Awards

6.00 -7.00pm Hall 4

COPD8 Opening Reception Thursday 21st June (am)

7.45 - 8.45am

ME7 Increasing activity as a focus of COPD therapeutics Media Suite
  Prof Rich Casaburi (USA)

ME8 GlaxoSmithKline: Practical application of the updated GOLD guidance Hall 11b
  Prof Wisia Wedzicha (UK), Prof Jorgen Vestbo (Den) & Prof Paul Jones (UK)

ME9 Almirall: 24 hours in the life of a COPD patient Exec Rm 1
  Prof Dennis Shale (UK)

ME10 Novartis: Implementing treatment guidelines
  - appropriate use of bronchodilators Exec Rm 2
  Prof David Price (UK)

ME11 Boehringer Ingelheim: Can we afford not to follow guidelines? Hall 11a
  Exacerbation management and the reality of clinical practice
  Dr John O’Reilly (UK) & Dr Richard Russell (UK)

9.00 -10.45am Hall 1

PS3.  Challenges of COPD diagnosis and integrated care
9:00 Challenge 1: Making the diagnosis – implications for patients Prof Peter Calverley (UK)
9:20 Challenge 2: Improving primary care diagnosis and management Prof David Price (UK)
9:40 Challenge 3: Integrated care – towards holistic management Dr Richard Mularski (USA)
10:00 Round table discussion

10.45 – 11.15am Refreshment Break Hall 4

11.15am – 12.45pm

BS2. The COPD Scientific year in perspective (1) Hall 11b
Technological advances has led to information overload in the study of ‘omics’.
This session provides a realistic update of these advances
Chair: Prof Gary Anderson (Aus) & Prof David Lomas (UK)
11:15 Introduction: How do we handle information overload Prof Gary Anderson (Aus)
11:25 Microbiome Prof Fernando Martinez (USA)
11:40 Biomarkers Prof Bart Celli (USA)
11:55 Inflammation cytokines Prof Alvar Agusti (Spain)
12:10 Immunology Prof Guy Brusselle (Bel)
12:25 Panel discussion

CS2. Nature or nurture Hall 11a
This session will review the evidence that COPD is predetermined making the smoker susceptible
Chair: Prof Sonia Buist (USA) & Dr Byron Thomashow (USA)
11:15 Introduction: Why would COPD run in families Prof Sonia Buist (USA)
11:25 Early life influences Prof Janet Stocks (UK)
11:45 Is there a genetic predisposition that makes sense? Prof James Crapo (USA)
12:05 Lung development and population studies Prof David Mannino (USA)
12:25 Panel discussion

CD2. Rehabilitation and reablement Hall 1
This session will provide an update on new developments in pulmonary rehabilitation
and in other aspects of the psychosocial care of patients
Chair: Prof Marc Decramer (Belg) & Prof Rich Casaburi (USA)
11:15 Tim Griffiths Memorial Lecture
  Achieving consistent outcomes and standards in pulmonary rehabilitation:
  what have we learned and what do we still need to do ? Prof Sally Singh (UK)
11:35 Neurocognitive aspects – how do we include them? Prof David Halpin (UK)
11:55 Pulmonary rehabilitation after exacerbations
  – is there a clear case? Prof Thierry Troosters (Belg)
12:15 Prescribing exercise – achieving an Olympic legacy Prof Mike Morgan (UK)
12:35 Panel discussion

12.45 – 1.45pm Lunch Break Hall 4

Thursday 21st June (pm)

1.45 – 3.45pm Hall 1
PS4.  ‘Infection’ and COPD – an update
  Arbitration Panel: Prof David Price (UK) & Prof Peter Calverley (UK)
1:45 Infective phenotypes – do they exist? Dr Marc Miravitlles (Spain)
2:00 Do colds influence the nature of exacerbations? Prof Sebastian Johnston (UK)
2:15 Should we characterise exacerbations? - Con Prof Rob Stockley (UK)
  - Pro Prof Wisia Wedzicha (UK)
2:45 Can we identify early and should we intervene despite patients view? Dr Shawn Aaron (Can)
3:00 Round table discussion
 

3.45 – 4.15pm Refreshment Break Hall 4

4.15 – 6.15pm

BS3. COPD models Hall 11b
This session describes new models being used to explore the pathophysiology of COPD
Chair: Prof Moira Whyte (UK)
4:15 Introduction: What contributes an ideal model / models Prof Moira Whyte (UK)
4:25 Skin models Prof Ian Sabroe (UK)
4:45 Endotoxin challenge Prof Dave Singh (UK)
5:05 Explanted lung Prof Paul Corris (UK)
5:25 Bio-artificial lung Dr Matthew Hind (UK)
5:45 Zebra fish Prof Steve Renshaw (UK)
6:05 Panel discussion

4.15 – 5.45pm

CS3. The roll of fat in COPD Hall 11a
This session explains how body habitas not only affects management but also influences the pathophysiology of COPD
Chair: Prof Emil Wouters (NL) & Prof Denis O’Donnell (Can)
4:15 Metabolic phenotype and adipose tissue inflammation in COPD Prof Ruzena Tkacova (Slovakia)
4:30 Influence on inflammation Prof Guy Brusselle (Belg)
4:45 Influence on mechanics/physiology Prof Denis O’Donnell (Can)
5:00 Implications for the management of COPD Prof Emil Wouters (NL)
5:15 Panel discussion

CD3. Getting some of the basics right Hall 1
This session will revisit some of the important interventions in preventing COPD and managing the disease and its symptoms in the later stages
Chair: Sam Prigmore (UK) & Dr Robert Winter (UK)
4:15 Oxygen assessments and review Prof Wisia Wedzicha (UK)
4:30 Crisis breathlessness Vikki Knowles (UK)
4:45 Domiciliary NIV: When is it needed? Dr Rob Angus (UK)
5:00 End of life care – can we do it better Helen Sorenson (USA)
5:15 Panel discussion

Friday 22nd June (am)

7.45-8.45am

ME12 World wide spirometry training Media Suite
Julie Lloyd (UK)

ME13 Acute NIV - who to ventilate Hall 8a
Dr Rob Angus (UK)

ME14 Education & Training Hall 8b
Monica Fletcher (UK) and Prof Christine Jenkins (Aus)

9.00 -10.30am

BS4. The COPD Scientific year in perspective (2) Hall 8a
This provides an update on the understanding of mechanistic processes that direct current and future therapies
Chair: Prof Rob Stockley (UK)
9:00 Introduction Prof Rob Stockley (UK)
9:05 Alpha-1 Prof Gerry McElvaney (Ire)
9:20 Immunity Prof Gary Anderson (Aus)
9:35 Imaging Dr David Parr (UK)
9:50 Stem cells Prof David Lomas (UK)
10:05 Panel discussion

9.00 -11.00am

CS4. Exacerbations Hall 8b
This session updates our knowledge of COPD exacerbations exploring the changes in incidence and the understanding of the clinical effects and course
Chair: Prof Wisia Wedzicha (UK) & Dr John Hurst (UK)
9:00 Introduction: Are exacerbations as important as they were? Dr John Hurst (UK)
9:10 Epidemiology Prof David Mannino (USA)
9:30 Are COPD exacerbations similar to asthma exacerbations Prof Ian Pavord (UK)
9:50 Physiology changes Dr Gavin Donaldson
10:10 Mechanisms of recovery Prof Wisia Wedzicha (UK)
10:30 Panel discussion

CD4. Achieving Quality outcomes in COPD Hall 5
This session will describe key elements of a holistic approach to improving outcomes for people living and working with COPD
Chair: Prof Sue Hill (UK) & Prof Sonia Buist (USA)
9:00 Introduction – ‘The outcomes based approach in England’ Prof Sue Hill (UK)
9:20 Using data to drive improvements Dr Robert Winter (UK)
9:40 Amenable mortality Prof Steve Rennard (USA)
10:10 Measuring patient experience: Do we have the right tools? Prof Paul Jones (UK)
10:30 COPD and the impact on work: How can we keep people
  actively employed? Monica Fletcher (UK)
  & John Walsh (USA)
10:50 Panel discussion

11.00 – 11.30am Refreshment Break

11.30am – 1.30pm Hall 5

PS5.  Can COPD treatment be personalised: Triumphs and disappointments
  Arbitration Panel: Prof Paula Meek (USA) & Prof Steve Rennard (USA)

11:30 Patient expectations Dame Helena Shovelton (UK) & John Walsh (USA)
  Achieving personalised treatment of COPD based on
12:00 - clinical phenotype & genotype (COPD gene) Prof James Crapo (USA)
12:15 - phenotypes & biomarkers Prof David Lomas (UK)
12:30 - using the GOLD approach Prof Jorgen Vestbo (Den)
12:45 - overlap syndrome Prof Chris Brightling (UK)
1:00 Debate: This house thinks it is a waste of time
1.25 Close of Conference Prof Sue Hill (UK) & Prof Rob Stockley (UK)